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1 These authors contributed equally to the work repMyostatin deﬁciency leads to both an increased rate of protein synthesis and skeletal muscle hyper-
trophy. However, the mechanisms involved in mediating these effects are not yet fully understood.
Here, we demonstrate that genetic loss of myostatin leads to enhanced muscle expression of both
protein kinase B and mammalian target of rapamycin/S6K signalling components, consistent with
their elevated activity. This is associated with a reduction in the expression of PGC1a and COX IV,
proteins which play important roles in maintaining mitochondrial function. Furthermore, we show
that these changes in signalling and protein expression are largely independent of alterations in
intramuscular amino acid content. Our ﬁndings, therefore, reveal potential new mechanisms and
further contribute to our understanding of myostatin-regulated skeletal muscle growth and
function.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Muscle atrophy, or a loss in muscle mass, can occur in response
to a variety of different conditions or metabolic disorders such as
aging, impaired respiratory function, cancer and diabetes [1–4].
Amongst the unfavourable effects that may arise from a reduction
in skeletal muscle mass include abated physical strength and
mobility, as well as the development of insulin resistance due to
its role as a metabolically active tissue.
Myostatin, or growth differentiation factor-8 (GDF-8), is a mem-
ber of the transforming growth factor-b (TGF-b) family of related
proteins which acts to negatively regulate skeletal muscle growth.
This inhibitory effect has been demonstrated mainly through its
genetic loss or mutation in a number of different species includingchemical Societies. Published by E
malian target of rapamycin;
orming growth factor-b; 4E-
g protein-1; rpS6, ribosomal
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proline-rich Akt substrate;
e atrophy F-box
ndal).
orted.humans [5–8]. More speciﬁcally, myostatin regulates the number
of muscle ﬁbres by inhibiting myogenic proliferation and differen-
tiation, effects which result from its binding and signalling through
cell-bound activin type II receptors expressed in this tissue [9–14].
Exposure of differentiated myotubes to growth factors such as
insulin-like growth factor-I (IGF-I) leads to a hypertrophic re-
sponse, characterised by an increase in myotube diameter and ele-
vated rate of protein synthesis [15,16]. Importantly, the induction
of protein synthesis by activation of protein kinase B (PKB) accom-
panied by mammalian target of rapamycin (mTOR)-mediated sig-
nalling is sufﬁcient to promote hypertrophy in skeletal muscle
both in vitro and in vivo [16,17].
mTOR, a key integrator of nutrient and growth factor signals,
regulates protein synthesis by phosphorylating both p70 ribosomal
protein S6 kinase (S6K) and eukaryotic translational initiation fac-
tor 4E-binding protein-1 (4E-BP1), respectively leading to their acti-
vation and inhibition. A number of studies have demonstrated that
myostatin acts as a negative regulator of mTOR-directed signalling
[11,13,18–21], consistent with its inhibitory effect on protein syn-
thesis, although the mechanisms by which it does so are not fully
understood. Here, we provide further insight into the myostatin-
mediated regulation of skeletalmusclemass by showing that genet-
ic loss of myostatin leads to the upregulation of PKB expression and
that of mTOR/S6K signalling components, namely S6K and its
downstream target ribosomal S6 protein (rpS6), concomitant withlsevier B.V. All rights reserved.
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demonstrate this response occurs largely in the absence of any sig-
niﬁcant change in intramuscular free amino acid content.
In addition, both PKB and mTOR have been implicated in the
regulation of mitochondrial function. However, whereas active
PKB promotes the downregulation in expression of peroxisome
proliferator-activated receptor-gamma coactivator-1a (PGC-1a), a
transcription coactivator involved in regulating mitochondrial bio-
genesis [22], pharmacological inhibition of mTOR by rapamycin
has been shown to suppress transcription of genes involved in
mitochondrial oxidative function [23]. Therefore, we determined
the expression of two key proteins important for mitochondrial
oxidative function, namely PGC-1a and COX IV. We demonstrate
here markedly reduced expression of both proteins under circum-
stances when PKB and mTOR/S6K signalling are simultaneously
elevated in response to myostatin deﬁciency. Our observations
are fully consistent with a switch towards an increased proportion
of fast-twitch glycolytic type muscle ﬁbres and also provide a pos-
sible explanation for the associated changes in protein synthesis,
muscle mass and nutrient metabolism in skeletal muscle of myost-
atin deﬁcient animals.2. Materials and methods
2.1. Materials
Antibodies against PKB, phospho-PKB-Ser473, phospho-
p70S6K-Thr389, phospho-p44-42 MAPK-Thr202/Tyr204, p44-42
MAPK, phospho-S6-Ser240/244 and S6 were all from New
England Biolabs (Beverley, MA). GAPDH antibody was from Sigma
(Poole, UK). Antibody against cytochrome c oxidase subunit IV
(COX IV) was from Invitrogen (Madison, WI). PGC-1a antibody
was purchased from Calbiochem (La Jolla, CA). HRP (horseradish
peroxidase)-conjugated anti-(rabbit IgG) and anti-(mouse IgG)
were obtained from New England Biolabs (Beverley, MA). All other
chemicals were from Sigma–Aldrich unless otherwise stated.2.2. Generation of myostatin-deﬁcient mice
Animal studies were performed in accordance with the
guidelines of the NIH Animal Care and Use Committee. Mice
carrying a targeted mutation in the myostatin gene (MSTN-KO)
[6] were produced from matings between heterozygotes that
had been backcrossed six times into the C57BL/6 genetic
background and genotyped as described [24]. Only male mice
aged between 30 and 32 weeks were used to obtain all data
presented.2.3. Western blot analysis
Gastrocnemius muscle was isolated from mice, snap frozen in
liquid nitrogen and homogenised in lysis buffer [50 mM Tris/HCl
(pH 7.4), 0.27 M sucrose, 1 mM sodium orthovanodate, 1 mM
EDTA, 1 mM EGTA, 10 mM sodium b-glycerophosphate, 50 mM
NaF, 5 mM sodium pyrophosphate, 1% (v/v) Triton X-100, 0.1%
2-mercaptoethanol and protease inhibitors]. Cell lysates (40 lg)
were subjected to SDS/PAGE on a 10% resolving gel and immu-
noblotted as previously described [25]. Immobilon-P membranes
(Millipore, Bedford, MA) were probed with primary antibodies as
indicated in the ﬁgure legends. Primary antibody detection was
performed with the appropriate HRP (horseradish peroxidase)-
conjugated anti-rabbit or anti-mouse IgG and resulting signals
visualised using enhanced chemiluminescence by exposure to
Konica Minolta X-ray autoradiographic ﬁlm.2.4. Amino acid analysis by HPLC
Muscle extracts were prepared for and analysed using HPLC as
previously described [26]. Brieﬂy, 20 mg of muscle tissue was
homogenised in 12% PCA followed by derivatization using a mix-
ture of ethanol, dH2O, TEA and phenylisothiocyanate (PITC) in a
7:1:1:1 ratio. The resulting phenylthiocarbamyl peptides were sep-
arated by a Hewlett Packard 1050 HPLC system (Minnesota, USA)
using standard protocols. Comparison of retention times using
amino acid standards was used to identify individual amino acids
together with relative changes in peak size to measure their
abundance.
2.5. Statistical analysis
Statistical signiﬁcance was determined by one way analysis of
variance (ANOVA) using GraphPad Prism software. Data was con-
sidered statistically signiﬁcant at P-values <0.05.3. Results and discussion
3.1. Elevated levels of PKB and mTOR/S6K signalling components
present in skeletal muscle of myostatin-deﬁcient mice
Activation of both the PI3K/PKB and mTOR/S6K pathways have
been implicated as important signalling events involved in mediat-
ing increases in skeletal muscle mass, primarily by activating
important downstream targets responsible for protein translation
initiation and protein synthesis [15,27]. Previous studies have
established that inhibiting myostatin function may lead to in-
creased myoﬁbrillar protein synthesis and skeletal muscle hyper-
trophy [5,6,28–30]. To investigate the mechanism(s) by which
myostatin acts to regulate these processes, we assessed the expres-
sion and phosphorylation status of PKB and components of the
mTOR/S6K pathway in myostatin-deﬁcient mice (MSTN-KO). In
comparison to wild type littermate control (WT) mice, PKB expres-
sion is signiﬁcantly elevated by 1.8-fold along with a signiﬁcant in-
crease in PKB activity in the gastrocnemius muscle of MSTN-KO
mice (Fig. 1). This is consistent with a previous study by Morissette
et al. demonstrating a similar increase in PKB activity in accor-
dance with elevated mRNA and protein levels of PKB in this same
animal model [31]. However, in contrast to that study, we also ob-
serve a marked increase (both around 3-fold) in (rpS6) expression
and that of its upstream kinase, S6K, thereby providing a likely
explanation for the elevated levels of phosphorylated rpS6 at
Ser240/244 in the MSTN-KOs (Fig. 1). It is unclear what may ac-
count for the observed differences in these studies, but it is plausi-
ble that differences in animal age as well as use of different muscle
types may account for these contrasting ﬁndings. Our study used
gastrocnemius muscle extracts from mice of 30–32 weeks of age,
whereas Morissette et al. used quadriceps muscle from much
younger animals (8–20 weeks of age). Therefore, further work will
be required to establish whether distinct mechanisms underlie the
development of hypertrophy with age in different muscle types.
The upregulation of PKB/mTOR/S6K signalling in MSTN-KO
mice is consistent with the reciprocal down-regulation of these
proteins by myostatin and would, at least in part, explain the in-
crease in protein synthesis and muscle hypertrophy observed in
these animals. However, this increase in protein expression is not
all-inclusive as, for instance, the levels of GAPDH remain unaltered
whilst those of ERK1/2 actually signiﬁcantly decrease (1.7-fold) in
the MSTN-KOs (Fig. 1). The reduction in total ERK1/2 expression is
also reﬂected by a lower level of its phosphorylation although the
difference did not reach statistical signiﬁcance in this case. This is a
surprising observation given the role of ERK1/2 both as a key
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Fig. 1. Effect of myostatin deﬁciency on PKB, S6K and ERK1/2 protein expression and activity in skeletal muscle. Gastrocnemius muscle was isolated from wild type control
(WT) or homozygous myostatin knockout (MSTN-KO) mice and resulting tissue extracts immunoblotted using the indicated antibodies. Representative immunoblots and
corresponding quantiﬁcations are shown. Each bar represents the mean ± S.E.M. for four individual animals. Asterisks indicate statistically signiﬁcant differences versus wild
type (WT) animals. *P < 0.05; NS, not signiﬁcant.
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by it has been shown to positively regulate protein synthesis
[32,33]. Our data, therefore, suggests that inhibiting myostatin
function does not promote growth through the elevation of
ERK1/2 activity. This observation is, however, consistent with a
previous study demonstrating that myostatin can activate rather
than inhibit the Ras/Raf/ERK1/2-cascade in C2C12 myoblasts and,
in doing so, implicates a role for this pathway in myostatin-medi-
ated inhibition of muscle cell growth and differentiation [34]. In-
deed, this may also be part of a counter-regulatory response to
accelerated muscle growth. In addition to these changes in PKB/
mTOR/S6K signalling components, we cannot exclude the possibil-
ity that autocrine production of upstream regulators such as mus-
cle-derived growth factors may also be co-ordinately regulated.
However, we observe no signiﬁcant difference in the expression
of mechano growth factor (MGF or IGF-1Eb in rodents) in muscle
obtained from WT and MSTN-KO mice at the level of mRNA (data
not shown), consistent with previous studies showing little change
or even a slight decrease in IGF-1 expression with myostatin-deﬁ-
ciency [35–37]. On the other hand, these same studies demon-
strate signiﬁcant increases in IGF-2, a pro-myogenic growth
factor, in response to loss of myostatin function [35–37]. Therefore,
additional work will be required to determine the individual con-
tribution of such upstream regulators upon cellular signalling
and hypertrophy resulting from myostatin-deﬁciency.
What purpose may regulation of PKB/mTOR/S6K signalling by
myostatin serve? Firstly, although induction of PKB/mTOR/S6K sig-
nalling promotes muscle hypertrophy, it has been shown that acti-vation of PKB by either insulin or growth factors alone is not
sufﬁcient to induce a hypertrophic response even in the presence
of amino acids [38]. In addition, inhibition of mTOR activity does
not completely block hypertrophy in response to loss of myostatin
function [30,31]. This therefore suggests that PKB and mTOR/S6K
may, at least to some extent, act synergistically to promote a full
hypertrophic response and that the induction of both PKB and
S6K/rpS6 expression and activity may be required to convey the
MSTN-KO phenotype. Secondly, as well as being important for
the modulation of protein synthesis through effects on protein
translation, it has also recently been shown that S6K1 can directly
phosphorylate Rictor, a component of mTOR complex-2 (mTORC2)
[39]. Although the phosphorylation of Rictor by S6K1 does not lead
to major changes in mTORC2-kinase activity, it can alter interac-
tions of this complex with other proteins including 14-3-3 pro-
teins. Therefore, upregulation of S6K expression and activity can
itself act as an additional signalling input into mTORC2 by poten-
tially altering its activity towards other target proteins that may
be involved in the hypertrophic response.
With regards to PKB, it is now well established that it can in-
duce protein synthesis by phosphorylating and inhibiting the
tuberous sclerosis (TSC1/TCS2) complex, a negative regulator of
mTOR [40]. In addition, PKB also phosphorylates PRAS40 (pro-
line-rich Akt substrate-40) [41]. Although the exact function(s) of
PRAS40 is still unknown, it has been shown to bind mTOR, via Rap-
tor, leading to the suppression of mTOR activity [42,43]. Therefore,
in both these cases, elevated PKB activity would further contribute
towards induced mTOR/S6K signalling.
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Fig. 2. Comparison of amino acid proﬁles of gastrocnemius muscle obtained from
wild type and myostatin-deﬁcient mice. Gastrocnemius muscle isolated from
individual wild type (WT) and myostatin deﬁcient (KO) mice was prepared for and
subjected to HPLC analysis in order to determine; (A) the total content of amino
acids or (B) the concentration of the individual amino acids indicated. Data are
presented as mean ± S.E.M. (n = 5 animals group). *P < 0.05 relative to WT.
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protein degradation. One such target of PKB in this process are the
forkhead box O (FoxO) transcription factors. PKB phosphorylates
FoxO proteins preventing their translocation into the nucleus,
thereby suppressing their transcriptional activity towards genes
encoding the E3 ubiquitin ligases muscle RING ﬁnger protein-1
(MuRF1) and muscle atrophy F-box (MAFbx), both of which medi-
ate ubiquitin-mediated proteasomal degradation and are thought
to be involved in the development of muscle atrophy [44]. In the
case of MSTN-KO mice, the higher levels of PKB activity would be
expected to suppress transcription of these atrogenes, although
surprisingly, a previous study has shown that their levels either re-
main unaltered or are actually increased in myostatin-deﬁcient
mice, possibly representing a counter-regulatory response to an in-
crease in muscle mass [31]. Consistent with this, although over-
expressing myostatin causes skeletal muscle atrophy it does not
appear to alter activity of the ubiquitin-proteasome pathway
[19]. Likewise, exposing cultured myotubes to myostatin results
in reduced protein synthesis but has no signiﬁcant effect on the
rate of protein degradation [10]. This therefore raises the issue as
to whether manipulating myostatin function is itself sufﬁcient to
modulate proteasomal-mediated degradation, or whether there
may be additional factors involved that it may act in conjunction
with to mediate its effects. Also, we cannot exclude the possibility
that myostatin acts to regulate other proteolytic mechanisms (e.g.
lysosmal protein degradation) in vivo.
3.2. Myostatin modulation of amino acid composition in skeletal
muscle
Due to the marked effects of myostatin deﬁciency upon muscle
mass and signalling involved in regulating protein synthesis, we
wanted to further explore the possibility that loss of myostatin
function may also cause enhanced muscle growth by modulating
amino acid composition within this tissue. To do this, gastrocne-
mius muscle was isolated from ﬁve wild type and ﬁve MSTN-KO
non-fasted mice, and then subjected to HPLC analysis in order to
compare the relative abundance of the 12 amino acids indicated
in Fig. 2. By this analysis, despite the increase in mean gastrocne-
miusmusclemass (70% from 156 mg to 265 mg) and corresponding
overall intramuscular amino acid pool size in MSTN-KOs, there was
little difference in total intramuscular amino acid content between
MSTN-KO and WT mice when expressed as an amount per mg of
muscle tissue (Fig. 2A). This therefore suggests that enhanced
muscle growth and changes in myocellular signalling observed in
MSTN-KO mice occur independently of total intramuscular amino
acid concentration.
However, three out of the 12 amino acids analysed were found
to have their concentrations signiﬁcantly altered in response to
myostatin deﬁciency, with levels of isoleucine increased by 56%
and those of aspartate and glycine reduced and increased by
around 40%, respectively (Fig. 2B). Isoleucine, a branched amino
acid, has previously been shown to activate S6K and regulators of
mRNA translation in skeletal muscle [45,46]. Therefore, its elevated
levels in MSTN-KO mice may contribute towards enhanced protein
synthesis and the hypertrophic phenotype of these animals. In
addition, administration of isoleucine has also been demonstrated
to convey a hypoglycaemic effect involving increased glucose up-
take into skeletal muscle – one of the phenotypic attributes of
MSTN-KO mice [47,48]. The fact that glycine is selectively upregu-
lated in MSTN-KO mice is surprising but a previous study has
shown that administering glycine can counteract myoﬁbrillar pro-
teolysis by downregulating atrophic and proteolytic-related genes
[49]. Therefore, it is possible that this increase in muscle glycine
content may further augment the hypertrophic response by sup-
pressing proteolysis.3.3. Myostatin deﬁciency reduces oxidative capacity in skeletal muscle
The multifarious functions of skeletal muscle arise from differ-
ences in ﬁbre type distribution which is primarily responsible for
the metabolic diversity found in this tissue. This variation in met-
abolic makeup can be further altered under different pathophysio-
logical conditions. For instance, factors such as physical inactivity
and insulin resistance all coincide with an overall reduced oxida-
tive capacity [50,51]. In contrast, increased physical activity, asso-
ciated with improved insulin sensitivity, elevates expression of
oxidative enzymes whilst reducing those with glycolytic activity
[50–52]. Therefore, we wanted to determine whether myostatin
deﬁciency alters the expression of peroxisome proliferator-acti-
vated receptor-gamma coactivator-1a (PGC-1a), a key regulator
of mitochondrial biogenesis, and of COX IV, the terminal enzyme
in the electron transport chain in mitochondria. As shown in
Fig. 3, the expression of both PGC-1a and COX IV is signiﬁcantly re-
duced by 3 and 2.2-fold respectively in the gastrocnemius muscle
of MSTN-KO compared to wild type mice, indicative of a reduction
in oxidative capacity. Therefore, interestingly, our data suggests
that loss of myostatin function leads to a ﬁbre type distribution
more characteristic of an insulin resistant state, despite myosta-
tin-deﬁcient mice displaying increased insulin sensitivity and
resistance to diet-induced obesity [48,51,53]. However, our obser-
vations are consistent with previous work demonstrating that ge-
netic loss of myostatin promotes a shift towards a fast glycolytic
phenotype [36,54–56]. In addition, the downregulation of PGC-
1a and COX IV expression is in accordance with reduced lipid oxi-
dation in skeletal muscle of MSTN-KO mice [48,57,58]. Further
work will be required to determine whether the loss in expression
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Fig. 3. Effect of myostatin deﬁciency on PGC-1a and COX IV protein expression in
skeletal muscle. Gastrocnemius muscle was isolated from wild type control (WT) or
homozygous myostatin knockout (KO) mice and resulting tissue extracts immuno-
blotted for PGC-1a and COX IV. Representative immunoblots and corresponding
quantiﬁcations are shown. Each bar represents the mean ± S.E.M. for three
individual animals. Asterisks indicate statistically signiﬁcant differences versus
wild type (WT) animals. *P < 0.05.
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tion of oxidative Type I ﬁbres present or if more acute inhibition of
myostatin signalling, perhaps in cultured myotubes, can mimic this
response. Again, the question remains as to whether the loss of
myostatin signalling is directly causing the ﬁbre type switch or if
this is part of a feedback response to accelerated muscle growth.
In conclusion, maintenance of skeletal muscle mass and func-
tion is crucial for proper regulation of blood glucose levels and lipid
metabolism. Importantly, myostatin plasma levels and expression
in muscle have been shown to be elevated in obesity and with pro-
gressive aging [59–61]. In accordance with this, recent studies have
shown that inhibition of myostatin signalling either by the devel-
opment of pharmacological inhibitors or otherwise may prove to
be beneﬁcial in the treatment of metabolic disorders such as Type
II diabetes or for increasing skeletal muscle mass in patients with
muscle-wasting diseases [48,62,63]. The ﬁndings presented in this
study demonstrate some degree of selectivity by which such a
course of treatment may have upon cellular signalling, although
further work will be required to fully elucidate the consequences
of modulating myostatin function upon other signalling systems.
Only then can a more comprehensive understanding of its down-
stream effects and therefore its viability as a potential therapeutic
target be acquired.
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